Radiopharm's RAD 101 Achieves 92% MRI Concordance in Phase 2b Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: Newsfilter
- Clinical Trial Results: In the U.S. Phase 2b clinical trial, 92% (11/12) of patients treated with RAD 101 achieved concordance with MRI, significantly boosting confidence in the drug's success and laying a strong foundation for initiating pivotal studies by the end of 2026.
- Market Potential Assessment: Independent commercial evaluations estimate RAD 101's U.S. market opportunity at over $500 million, indicating its potential to become one of the top three imaging agents in the market, thereby providing robust support for the company's future revenue growth.
- Patient Management Transformation: By integrating RAD 101 PET with standard MRI, it is expected to enhance treatment decisions for over 300,000 patients diagnosed with brain metastases annually in the U.S., improving patient management efficiency and optimizing treatment outcomes.
- Trial Progress: The company has achieved 50% patient enrollment in the Phase 2b trial and received FDA Fast Track Designation, further enhancing RAD 101's prospects in brain metastasis imaging.
Analyst Views on RADX
Wall Street analysts forecast RADX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RADX is 20.33 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.050
Low
15.00
Averages
20.33
High
30.00
Current: 5.050
Low
15.00
Averages
20.33
High
30.00
About RADX
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
